4Q EARNINGS: Is 2015 Lilly's turning point?
This article was originally published in Scrip
Executive Summary
Eli Lilly's revenue fell 15% to $19.6bn in 2014 from $23.1bn in 2013, largely due to patent expirations for two of its top-selling products, but the company believes that 2015 could be the year that things turn around and investors seemed to agree.